OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
readouts and regulatory steps clustered into 2026 and early 2027. The setup makes the next several quarters especially event-driven. For investors, the key is how cleanly timelines hold. With rolling submissions, interim looks, and pivotal readouts all on the calendar, execution can drive sharp moves in either direction. OCGN's 2026 Catalyst Calendar for Three Eye Programs 2026 is positioned as a pivotal year because each of Ocugen's lead eye programs is scheduled to generate meaningful updates, including clinical readouts and regulatory progress that can reframe expectations quickly. The company's overall narrative centers on advancing differentiated gene therapies for retinitis pigmentosa, Stargardt disease, and geographic atrophy, all areas with high unmet need. Ocugen also plans to file three regulatory applications over the next three years. Ocugen's OCU400 Nears Filing With Phase III Complete OCU400 is the lead modifier gene therapy candidate for retinitis pigmentosa
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [Yahoo! Finance]Yahoo! Finance
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [TheStreet.com]TheStreet.com
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt DiseaseGlobeNewswire
- Ocugen (OCGN) Reveals OCU410 Clinical Trial Data [Yahoo! Finance]Yahoo! Finance
- How The Ocugen (OCGN) Narrative Is Shifting With Retinal Gene Therapy Data And New Valuations [Yahoo! Finance]Yahoo! Finance
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/27/26 - Form 8-K
- 3/24/26 - Form 8-K
- OCGN's page on the SEC website